Payment overview · 2025
General Payments
$30.12
2 reported records · 2 companies
Healthcare provider profile · identity verified
Ronald A Evans, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BOLIVAR, MO · NPI 1679595102
Verified facts
What the public records show
CMS Open Payments records show Ronald A Evans, M.D. received $30.12 in general payments during 2025 across 2 reported records.
Amgen Inc. accounted for 51.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Lumigan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.36 | 51.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.76 | 49.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $30.12 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.76 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 717 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 642 | 84 |
| Eliquis | Apixaban | 427 | 50 |
| Losartan Potassium | Losartan Potassium | 406 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 404 | 84 |
| Gabapentin | Gabapentin | 396 | 63 |
| Lisinopril | Lisinopril | 358 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 343 | 76 |
| Omeprazole | Omeprazole | 313 | 67 |
| Potassium Chloride | Potassium Chloride | 281 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 261 | 42 |
| Furosemide | Furosemide | 259 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 249 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 213 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 212 | 60 |
| Metformin Hcl Er | Metformin Hcl | 203 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 187 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 31 |
| Mirtazapine | Mirtazapine | 182 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 36 |
| Sertraline Hcl | Sertraline Hcl | 160 | 27 |
| Warfarin Sodium | Warfarin Sodium | 157 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 38 |
| Metformin Hcl | Metformin Hcl | 148 | 44 |
| Trazodone Hcl | Trazodone Hcl | 146 | 32 |
| Tramadol Hcl | Tramadol Hcl | 142 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 133 | 36 |
| Donepezil Hcl | Donepezil Hcl | 123 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 122 | suppressed |
| Carvedilol | Carvedilol | 121 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 28 |
| Spironolactone | Spironolactone | 107 | 27 |
| Bumetanide | Bumetanide | 104 | 13 |
| Buspirone Hcl | Buspirone Hcl | 99 | 22 |
| Montelukast Sodium | Montelukast Sodium | 98 | 17 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 96 | 21 |
| Klor-Con M20 | Potassium Chloride | 87 | 12 |
| Lorazepam | Lorazepam | 84 | 19 |
| Latanoprost | Latanoprost | 83 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 18 |
| Finasteride | Finasteride | 81 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 78 | 14 |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 78 | 14 |
| Ozempic | Semaglutide | 77 | 14 |
| Simvastatin | Simvastatin | 76 | 17 |
| Alendronate Sodium | Alendronate Sodium | 73 | 17 |
| Allopurinol | Allopurinol | 73 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 13 |
| Alprazolam | Alprazolam | 70 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 69 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | suppressed |
| Januvia | Sitagliptin Phosphate | 65 | 11 |
| Baclofen | Baclofen | 61 | 13 |
| Divalproex Sodium | Divalproex Sodium | 59 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 59 | suppressed |
| Pregabalin | Pregabalin | 56 | suppressed |
| Myrbetriq | Mirabegron | 55 | suppressed |
| Lovastatin | Lovastatin | 53 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 52 | 11 |
| Atenolol | Atenolol | 51 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 47 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Famotidine | Famotidine | 44 | 12 |
| Tradjenta | Linagliptin | 44 | suppressed |
| Primidone | Primidone | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 17 |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 40 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Jardiance | Empagliflozin | 39 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 39 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 38 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 34 | 34 |
| Colestipol Hcl | Colestipol Hcl | 34 | suppressed |
| Cephalexin | Cephalexin | 33 | 20 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 32 | suppressed |
| Movantik | Naloxegol Oxalate | 31 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 21 |
| Diltiazem 24hr Er | Diltiazem Hcl | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Lumigan | Bimatoprost | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Sulfasalazine | Sulfasalazine | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Carisoprodol | Carisoprodol | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Carbamazepine | Carbamazepine | 22 | suppressed |
| Carbamazepine Er | Carbamazepine | 22 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 12 |
| Prednisone | Prednisone | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 12 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ethosuximide | Ethosuximide | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30.12 · 2 records | Amgen Inc. | EVENITY, PROLIA, QULIPTA, UBRELVY | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error